Alloantibodies in von Willebrand Disease

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

von Willebrand disease (VWD), the most commonly known inherited bleeding disorder, is caused by a partial (type 1) or total (type 3) deficiency or dysfunction (type 2) of von Willebrand factor (VWF). Its management encompasses the prevention or treatment of bleeding by raising endogenous VWF levels using a synthetic agent, such as desmopressin, or providing exogenous VWF concentrates. The development of inhibitory alloantibodies against VWF is a rare but often severe complication encountered during the treatment of type 3 VWD, which is associated with a lack of hemostatic response to infused VWF concentrates and more rarely with allergic, even anaphylactic, reactions. This narrative review will focus on the characteristics of such alloantibodies and their management, which can be very challenging for physicians operating at hemophilia treatment centers.

Original languageEnglish
Pages (from-to)590-594
JournalSeminars in Thrombosis and Hemostasis
Volume44
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Isoantibodies
von Willebrand Diseases
von Willebrand Factor
Type 3 Von Willebrand's Disease
Hemorrhage
Deamino Arginine Vasopressin
Hemophilia A
Anaphylaxis
Hemostatics
Therapeutics
Physicians

Keywords

  • alloantibodies
  • anaphylaxis
  • type 3
  • von Willebrand disease

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Alloantibodies in von Willebrand Disease. / Franchini, Massimo; Mannucci, Pier Mannuccio.

In: Seminars in Thrombosis and Hemostasis, Vol. 44, No. 6, 2018, p. 590-594.

Research output: Contribution to journalArticle

@article{cde3b22d452646c89b1dd3979cf63390,
title = "Alloantibodies in von Willebrand Disease",
abstract = "von Willebrand disease (VWD), the most commonly known inherited bleeding disorder, is caused by a partial (type 1) or total (type 3) deficiency or dysfunction (type 2) of von Willebrand factor (VWF). Its management encompasses the prevention or treatment of bleeding by raising endogenous VWF levels using a synthetic agent, such as desmopressin, or providing exogenous VWF concentrates. The development of inhibitory alloantibodies against VWF is a rare but often severe complication encountered during the treatment of type 3 VWD, which is associated with a lack of hemostatic response to infused VWF concentrates and more rarely with allergic, even anaphylactic, reactions. This narrative review will focus on the characteristics of such alloantibodies and their management, which can be very challenging for physicians operating at hemophilia treatment centers.",
keywords = "alloantibodies, anaphylaxis, type 3, von Willebrand disease",
author = "Massimo Franchini and Mannucci, {Pier Mannuccio}",
year = "2018",
doi = "10.1055/s-0037-1607440",
language = "English",
volume = "44",
pages = "590--594",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - Alloantibodies in von Willebrand Disease

AU - Franchini, Massimo

AU - Mannucci, Pier Mannuccio

PY - 2018

Y1 - 2018

N2 - von Willebrand disease (VWD), the most commonly known inherited bleeding disorder, is caused by a partial (type 1) or total (type 3) deficiency or dysfunction (type 2) of von Willebrand factor (VWF). Its management encompasses the prevention or treatment of bleeding by raising endogenous VWF levels using a synthetic agent, such as desmopressin, or providing exogenous VWF concentrates. The development of inhibitory alloantibodies against VWF is a rare but often severe complication encountered during the treatment of type 3 VWD, which is associated with a lack of hemostatic response to infused VWF concentrates and more rarely with allergic, even anaphylactic, reactions. This narrative review will focus on the characteristics of such alloantibodies and their management, which can be very challenging for physicians operating at hemophilia treatment centers.

AB - von Willebrand disease (VWD), the most commonly known inherited bleeding disorder, is caused by a partial (type 1) or total (type 3) deficiency or dysfunction (type 2) of von Willebrand factor (VWF). Its management encompasses the prevention or treatment of bleeding by raising endogenous VWF levels using a synthetic agent, such as desmopressin, or providing exogenous VWF concentrates. The development of inhibitory alloantibodies against VWF is a rare but often severe complication encountered during the treatment of type 3 VWD, which is associated with a lack of hemostatic response to infused VWF concentrates and more rarely with allergic, even anaphylactic, reactions. This narrative review will focus on the characteristics of such alloantibodies and their management, which can be very challenging for physicians operating at hemophilia treatment centers.

KW - alloantibodies

KW - anaphylaxis

KW - type 3

KW - von Willebrand disease

UR - http://www.scopus.com/inward/record.url?scp=85034753556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034753556&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1607440

DO - 10.1055/s-0037-1607440

M3 - Article

AN - SCOPUS:85034753556

VL - 44

SP - 590

EP - 594

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 6

ER -